bosentan anhydrous has been researched along with warfarin in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.17) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 15 (62.50) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Banken, L; Birnboeck, H; Schulz, R; Weber, C | 1 |
| Chakinala, MM | 1 |
| Barst, RJ; Berekashvili, KK; Horn, EM; Kawut, SM; Lederer, DJ; Rosenzweig, EB; Widlitz, AC | 1 |
| Häusler, S; Schneiter, R; Stieger, B; Treiber, A | 1 |
| Doherty, DR; Eipe, N; Lai, L | 1 |
| David, S; Feldman, D; Ghanbari, H; Saba, S | 1 |
| Saxena, S; Spangler, ML | 1 |
| Dunnington, GH; Johri, S; Vnencak-Jones, CL | 1 |
| Gaine, SP; Murphy, DM; Murphy, DT; Murray, JG | 1 |
| Fan, R; Fan, Y; Ji, R; Penny, DJ; Varghese, NP; Wang, G; Zou, W | 1 |
| Canestaro, WJ; Devine, BE; Forrester, SH; Ho, L; Raghu, G | 1 |
| Lejnieks, A; Lesina, K; Rudzitis, A; Sablinskis, K; Skride, A | 1 |
| Hirono, K; Ichida, F; Nakamura, S; Ozawa, S; Taguchi, M; Watanabe, N; Yoshimura, N | 1 |
| Hirono, K; Ichida, F; Ide, H; Mito, A; Ozawa, S; Taguchi, M | 1 |
3 review(s) available for bosentan anhydrous and warfarin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Changing the prognosis of pulmonary arterial hypertension: impact of medical therapy.
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Clinical Trials as Topic; Epoprostenol; Humans; Hypertension, Pulmonary; Piperazines; Prognosis; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Analysis; Warfarin | 2005 |
Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Azathioprine; Bayes Theorem; Bosentan; Endothelin Receptor Antagonists; Enzyme Inhibitors; Etanercept; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Interferon-gamma; Phenylpropionates; Pyridazines; Pyridones; Pyrimidines; Recombinant Proteins; Sulfonamides; Vital Capacity; Warfarin | 2016 |
1 trial(s) available for bosentan anhydrous and warfarin
| Article | Year |
|---|---|
Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin.
Topics: Adult; Anticoagulants; Antihypertensive Agents; Area Under Curve; Bosentan; Cross-Over Studies; Double-Blind Method; Endothelin Receptor Antagonists; Factor VII; Half-Life; Humans; Male; Prothrombin Time; Stereoisomerism; Sulfonamides; Warfarin | 1999 |
20 other study(ies) available for bosentan anhydrous and warfarin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension.
Topics: Adult; Bosentan; Cardiac Catheterization; Cohort Studies; Digoxin; Drug Administration Routes; Epoprostenol; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Transplantation; Male; Pulmonary Circulation; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sulfonamides; Survival Analysis; Treatment Outcome; Vasodilation; Warfarin | 2006 |
Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Biological Transport; Bosentan; CHO Cells; Cricetinae; Cricetulus; Cyclosporine; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dehydroepiandrosterone Sulfate; Drug Interactions; Enzyme Inhibitors; Estradiol; Estrone; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Piperazines; Purines; Pyrimidines; Rifampin; Sildenafil Citrate; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides; Sulfones; Warfarin | 2007 |
Severe pulmonary hypertension and adenotonsillectomy in a child with Trisomy-21 and obstructive sleep apnea.
Topics: Adenoidectomy; Anesthetics, Intravenous; Anticoagulants; Antihypertensive Agents; Bosentan; Child; Down Syndrome; Elective Surgical Procedures; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Intubation, Intratracheal; Piperazines; Piperidines; Propofol; Purines; Remifentanil; Severity of Illness Index; Sildenafil Citrate; Sleep Apnea, Obstructive; Sulfonamides; Sulfones; Tonsillectomy; Treatment Outcome; Vasodilator Agents; Warfarin | 2009 |
Unilateral absence of a left pulmonary artery: successful therapeutic response to a combination of bosentan and warfarin.
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Diagnostic Imaging; Drug Therapy, Combination; Electrocardiography; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Middle Aged; Pulmonary Artery; Sulfonamides; Warfarin | 2009 |
Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.
Topics: Anticoagulants; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Bosentan; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Hypertension, Pulmonary; International Normalized Ratio; Middle Aged; Pulmonary Embolism; Sulfonamides; Treatment Outcome; Warfarin | 2010 |
A novel BMPR2 mutation associated with pulmonary arterial hypertension in an octogenarian.
Topics: Aged, 80 and over; Amlodipine; Bone Morphogenetic Protein Receptors, Type II; Bosentan; Digoxin; Dyspnea; Humans; Hypertension, Pulmonary; Male; Pulmonary Artery; Sulfonamides; Warfarin | 2010 |
Case 1: chronic thromboembolic pulmonary hypertension (CTEPH).
Topics: Adult; Anticoagulants; Antihypertensive Agents; Bosentan; Chronic Disease; Diuretics; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Male; Pulmonary Embolism; Sulfonamides; Tomography, X-Ray Computed; Warfarin | 2013 |
Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: a case report.
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Child, Preschool; Codon, Nonsense; Epoprostenol; Growth Differentiation Factor 2; Growth Differentiation Factors; Homozygote; Humans; Hypertension, Pulmonary; Male; Mexican Americans; Sildenafil Citrate; Sulfonamides; Vasodilator Agents; Warfarin | 2016 |
First data from Latvian chronic thromboembolic pulmonary hypertension registry.
Topics: Adult; Age Distribution; Aged; Anticoagulants; Bosentan; Chronic Disease; Female; Humans; Hypertension, Pulmonary; Incidence; Latvia; Male; Middle Aged; Phenylpropionates; Prevalence; Pulmonary Embolism; Pyrazoles; Pyridazines; Pyridones; Registries; Rivaroxaban; Sex Distribution; Sildenafil Citrate; Sulfonamides; Vasodilator Agents; Warfarin; Young Adult | 2016 |
A model analysis for dose-response relationship of warfarin in Japanese children: An introduction of the SIZE parameter.
Topics: Adolescent; Anticoagulants; Body Weight; Bosentan; Child; Child, Preschool; Cytochrome P450 Family 4; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Genotype; Humans; Japan; Longitudinal Studies; Male; Models, Biological; Retrospective Studies; Sulfonamides; Vitamin K Epoxide Reductases; Warfarin | 2016 |
Effects of Concomitant Administration of PXR Ligand Drugs on the Anticoagulant Effects of Warfarin.
Topics: Anticoagulants; Bosentan; Child; Child, Preschool; Female; Humans; International Normalized Ratio; Ligands; Longitudinal Studies; Pharmaceutical Preparations; Pregnane X Receptor; Rifampin; Warfarin | 2022 |